VA launches PIVOT study to evaluate psilocybin for depression and PTSD in veterans

Published Aug 6, 07:22 PM UTC

Editorial responsibility

Prepared by: WorldAttention Editorial Systems
Human review: No named human review is recorded for this page.
Automated steps: Source reporting is collected, normalized, translated or condensed automatically when needed.
Page status: Automatically published source-backed update

How automation and AI are used · Report a correction or rights issue

The Department of Veterans Affairs is launching the PIVOT study to evaluate the safety and effectiveness of psilocybin, the psychoactive ingredient in magic mushrooms, for treating treatment-resistant major depressive disorder and PTSD in veterans. The double-blind, randomized trial will include at least 240 veterans across five VA medical centers, with participants receiving one or two doses of psilocybin or a placebo along with therapeutic support, and will run through June 2031. This follows a small Ohio State University study where 75% of veteran participants no longer met PTSD criteria after psilocybin treatment. The initiative is backed by a Trump executive order directing accelerated review of psychedelic therapies, and the VA is currently involved in 20 clinical trials on psychedelic treatments including MDMA and LSD.

Source

Army TimesWestern

Original headline: Major VA study to examine effectiveness of psilocybin on depression, PTSD

Original language: EN

Part of this Story

VA Launches Major Psilocybin Trial for Veteran PTSD and Depression

See the full Story: all sources and camp coverage

People and interests

Donald Trump Food and Drug Administration Department of Health and Human Services